{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:59:12Z","timestamp":1783965552028,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1067\/mjd.2002.122187","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T22:14:26Z","timestamp":1030227266000},"page":"495-504","source":"Crossref","is-referenced-by-count":295,"title":["Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents"],"prefix":"10.1067","volume":"46","author":[{"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Lucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewiczc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.B.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cherille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Marshalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bushe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Graeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2002.122187_bib1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0190-9622(86)70198-9","article-title":"Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample","volume":"15","author":"Larsen","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0091-6749(99)70536-1","article-title":"Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood","volume":"103","author":"Williams","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mjd.2002.122187_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2000.107773","article-title":"The prevalence of atopic dermatitis in Oregon schoolchildren","volume":"43","author":"Laughter","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02991185","article-title":"Natural history and clinical manifestations of atopic dermatitis","volume":"4","author":"Rajka","year":"1986","journal-title":"Clin Rev Allergy"},{"key":"10.1067\/mjd.2002.122187_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0190-9622(99)70410-X","article-title":"Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies","volume":"41","author":"Hanifin","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1067\/mai.2000.106484","article-title":"Atopic dermatitis: new insights and opportunities for therapeutic intervention","volume":"105","author":"Leung","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mjd.2002.122187_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1081-1206(10)63003-7","volume":"79","author":"Leung","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1067\/mjd.2002.122187_bib8","first-page":"144","article-title":"New concepts in atopic dermatitis","volume":"22","author":"Boguniewicz","year":"1996","journal-title":"Compr Ther"},{"key":"10.1067\/mjd.2002.122187_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2133.1997.tb03788.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology","volume":"137","author":"Meingassner","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib10","first-page":"240","article-title":"The efficacy, tolerability and safety of a new oral formulation of Sandimmun\u2014Sandimmun Neoral in severe refractory atopic dermatitis","volume":"11","author":"Atakan","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1067\/mjd.2002.122187_bib11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199709183371203","article-title":"A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group","volume":"337","author":"Ruzicka","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2002.122187_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/archderm.136.8.999","article-title":"Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis","volume":"136","author":"Reitamo","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1067\/mjd.2001.109813","article-title":"A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients","volume":"44","author":"Paller","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 4","key":"10.1067\/mjd.2002.122187_bib14","first-page":"149","article-title":"Oral SDZ ASM 981: safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis","volume":"114","author":"Rappersberger","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.1998.02554.x","article-title":"The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion","volume":"139","author":"Mrowietz","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2133.2000.03411.x","article-title":"Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981","volume":"142","author":"Neckermann","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2133.1999.02974.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology","volume":"141","author":"Grassberger","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archderm.134.7.805","article-title":"Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis","volume":"134","author":"van Leent","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib19","first-page":"523","article-title":"Pharmacokinetics of SDZ ASM 981 Cream 1% in adults and children","volume":"14","author":"Allen","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1067\/mjd.2002.122187_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","article-title":"The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI). Assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(97)12082-7","article-title":"Atopic dermatitis","volume":"351","author":"Rudikoff","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2002.122187_bib23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3928\/0090-4481-19981101-06","article-title":"Atopic dermatitis","volume":"27","author":"Woodmansee","year":"1998","journal-title":"Pediatr Ann"},{"key":"10.1067\/mjd.2002.122187_bib24","first-page":"532","article-title":"SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential","volume":"117","author":"Meingassner","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","article-title":"The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study","volume":"144","author":"Queille-Roussel","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1523-1747.ep12480966","article-title":"High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin","volume":"97","author":"van der Heijden","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0091-6749(96)70246-4","article-title":"In vivo expression of IL-12 and IL-13 in atopic dermatitis","volume":"98","author":"Hamid","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mjd.2002.122187_bib28","first-page":"2713","article-title":"FK 506: historical perspectives","volume":"23","author":"Goto","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1067\/mjd.2002.122187_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2002.122187_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0733-8635(18)30385-1","article-title":"A review and update of the clinical uses of cyclosporine in dermatology","volume":"9","author":"Groisser","year":"1991","journal-title":"Dermatol Clin"},{"key":"10.1067\/mjd.2002.122187_bib31","first-page":"832","article-title":"SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis","volume":"114","author":"Meingassner","year":"2000","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962202234222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962202234222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:41:20Z","timestamp":1680532880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962202234222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0190962202234222"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2002.122187","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}